Related Experiment Videos
Tranexamic acid in patients with hemoptysis
Jamsak Tscheikuna1, Benjamas Chvaychoo, Chana Naruman
1Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Summary
This study found tranexamic acid did not shorten hemoptysis duration in patients. However, the drug showed a low incidence of side effects during the trial.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Hemoptysis is a frequent respiratory symptom necessitating hospitalization.
- Current management focuses on treating the underlying cause, with limited evidence supporting tranexamic acid use.
Purpose of the Study:
- To evaluate the efficacy of tranexamic acid in reducing the duration of hemoptysis.
- To assess the safety and incidence of side effects associated with tranexamic acid in hemoptysis patients.
Main Methods:
- A randomized, double-blind, placebo-controlled trial was conducted over one week.
- Patients were categorized into three groups based on bleeding severity (blood-streaked sputum, <20 ml, or 20-500 ml/day).
- Bleeding amount and drug side effects were meticulously recorded.
Main Results:
- 46 patients completed the study (21 tranexamic acid, 25 placebo).
- The study did not demonstrate a significant benefit of tranexamic acid in shortening hemoptysis duration.
- A low incidence of tranexamic acid side effects was observed.
Conclusions:
- This trial could not confirm the benefit of tranexamic acid in reducing hemoptysis days.
- The study supports a low incidence of side effects for tranexamic acid in this patient population.